Rocket Pharmaceuticals director awarded stock, options

ROCKET PHARMACEUTICALS, INC. director Fady Ibraham Malik reported receiving equity awards tied to the company’s common stock.

Rhea-AI Filing Summary

ROCKET PHARMACEUTICALS, INC. director Fady Ibraham Malik reported receiving equity awards tied to the company’s common stock. He was granted 22,862 restricted stock units that convert into common shares on a one-for-one basis and will vest in full on June 18, 2027.

He also received a stock option covering 64,860 shares of common stock at an exercise price of $3.35 per share, which will become fully vested and exercisable on June 18, 2027 and expires on June 18, 2036. Following the RSU grant, he directly holds 52,862 common shares.

Insider Trade Summary

Grant/Award: 87,722 shares

Grant/Award 2 txns

Insider Malik Fady Ibraham

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	64,860	$0.00	$0.00
Grant/Award	Common Stock	22,862	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 64,860 contracts (Direct); Common Stock — 52,862 shares (Direct)

Footnotes (2)

1. F1. Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027.
2. F2. This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027.

Key Figures

RSU grant: 22,862 RSUs Stock option grant: 64,860 options Option exercise price: $3.35 per share +2 more

5 metrics

RSU grant 22,862 RSUs Restricted stock units vesting June 18, 2027

Stock option grant 64,860 options Right to buy common stock, vesting June 18, 2027

Option exercise price $3.35 per share Exercise price for 64,860-share stock option

Shares held after grant 52,862 shares Common stock directly owned following RSU award

Option expiration June 18, 2036 Expiration date of the 64,860-share option

Key Terms

restricted stock units ("RSUs"), Stock Option (Right to Buy), vest, exercise price

4 terms

restricted stock units ("RSUs") financial

"Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis."

Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.

Stock Option (Right to Buy) financial

"This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock"

vest financial

"The RSUs will vest in full on June 18, 2027."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

exercise price financial

"This option represents a right to purchase a total of 64,860 shares"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Rocket Pharmaceuticals (RCKT) director Fady Malik report in this Form 4?

Fady Malik reported receiving equity awards in Rocket Pharmaceuticals. He was granted 22,862 restricted stock units plus a stock option for 64,860 shares, both linked to common stock and vesting on June 18, 2027.

How many Rocket Pharmaceuticals (RCKT) RSUs were granted to Fady Malik?

Fady Malik received 22,862 restricted stock units. These RSUs convert into Rocket Pharmaceuticals common stock on a one-for-one basis and will vest in full on June 18, 2027 if the standard vesting conditions are satisfied.

What are the terms of Fady Malik’s new stock option in Rocket Pharmaceuticals (RCKT)?

He received a stock option for 64,860 shares of common stock at a $3.35 exercise price. The option becomes fully vested and exercisable on June 18, 2027 and expires on June 18, 2036, according to the filing footnote.

When do Fady Malik’s Rocket Pharmaceuticals (RCKT) RSUs and options vest?

Both the RSUs and the stock option vest on June 18, 2027. The RSUs then convert one-for-one into common shares, while the option becomes fully exercisable for 64,860 shares at the stated exercise price.

How many Rocket Pharmaceuticals (RCKT) common shares does Fady Malik hold after these grants?

After the RSU grant, Fady Malik directly owns 52,862 shares of Rocket Pharmaceuticals common stock. This figure reflects his holdings following the reported non-derivative acquisition transaction on June 18, 2026.

Did Fady Malik buy or sell Rocket Pharmaceuticals (RCKT) shares on the open market?

The filing shows grant or award acquisitions, not open-market trades. The reported transactions involve RSU and stock option awards with a zero transaction price, classified as grant or award acquisitions under transaction code A.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/06/2026 - 07:59 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Malik Fady Ibraham

(Last) (First) (Middle)

C/O ROCKET PHARMACEUTICALS, INC.

9 CEDARBROOK DRIVE

(Street)

CRANBURY NEW JERSEY 08512

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ROCKET PHARMACEUTICALS, INC. [ RCKT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	06/18/2026		A		22,862	A	$0(1)	52,862	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$3.35	06/18/2026		A		64,860		(2)	06/18/2036	Common Stock	64,860	$0	64,860	D

Explanation of Responses:

1. Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. The RSUs will vest in full on June 18, 2027.

2. This option represents a right to purchase a total of 64,860 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on June 18, 2027.

	/s/ Martin Wilson, as attorney-in-fact for Fady Ibraham Malik	07/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)